secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2025-10-21T23:59:59+00:00
Accession:  0001689548-25-000103
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Type B meeting for Praxis's ulixacaltamide in Q4 2025
----------------------------------------------------------------

- FDA granted a Type B meeting following review of Essential3 topline results for ulixacaltamide.
- Meeting to occur in Q4 2025; pre-NDA meeting request was previously disclosed.
- Corporate presentation updated and posted on investors.praxismedicines.com.
- No financial results or guidance changes included in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000103/0001689548-25-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000103/prax-20251020.htm
  HTML page:      https://secwatch.observer/filing/0001689548-25-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer